Calendario›REGN›cemiplimab

cemiplimab

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Carcinoma escamoso cutaneo.

Más ensayos de: Carcinoma escamoso cutáneo.

Fase

Fase 2

Estado

Retirado antes de empezar

Fin del objetivo primario

jun 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, abierto. Comenzó en nov 2024.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Business Decision».

Qué mide

Pathological complete response (pCR) rate by blinded independent pathological review (BIPR) (del registro, en inglés) (hasta 100 dias)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an investigational drug called REGN2810, also known as cemiplimab, and when combined with another investigational drug called REGN3767, also known as fianlimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on a type of skin cancer known as cutaneous squamous cell carcinoma (CSCC). The aim of the study is to see if cemiplimab or cemiplimab in combination with fianlimab can eliminate or reduce the number of living cancer cells in tumor(s) if taken before surgery. The study is looking at several other research questions, including: * Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make it possible to have a less extensive surgery or a different treatment plan after surgery * Whether taking cemiplimab or cemiplimab in combination with fianlimab before surgery may make the cancer less likely to come back after surgery * What side effects may happen from taking the cemiplimab or cemiplimab in combination with fianlimab * How much of the cemiplimab or cemiplimab in combination with fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the drug(s) less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06384820), actualizada en jul 2024.